請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/31434完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 林淑華 | |
| dc.contributor.author | Jiun-Sheng Chang | en |
| dc.contributor.author | 章竣升 | zh_TW |
| dc.date.accessioned | 2021-06-13T03:12:58Z | - |
| dc.date.available | 2006-09-18 | |
| dc.date.copyright | 2006-09-18 | |
| dc.date.issued | 2006 | |
| dc.date.submitted | 2006-08-31 | |
| dc.identifier.citation | 1.Somoza JR, Ho JD, Luong C, et al. The structure of the extracellular region of human hepsin reveals a serine protease domain and a novel scavenger receptor cysteine-rich (SRCR) domain. Structure. 2003;11:1123-1131.
2.Leytus SP, Loeb KR, Hagen FS, Kurachi K, Davie EW. A novel trypsin-like serine protease (hepsin) with a putative transmembrane domain expressed by human liver and hepatoma cells. Biochemistry. 1988;27:1067-1074. 3.Vu TK, Liu RW, Haaksma CJ, Tomasek JJ, Howard EW. Identification and cloning of the membrane-associated serine protease, hepsin, from mouse preimplantation embryos. J Biol Chem. 1997;272:31315-31320. 4.Tsuji A, Torres-Rosado A, Arai T, et al. Hepsin, a cell membrane-associated protease. Characterization, tissue distribution, and gene localization. J Biol Chem. 1991;266:16948-16953. 5.Kawamura S, Kurachi S, Deyashiki Y, Kurachi K. Complete nucleotide sequence, origin of isoform and functional characterization of the mouse hepsin gene. Eur J Biochem. 1999;262:755-764. 6.Torres-Rosado A, O'Shea KS, Tsuji A, Chou SH, Kurachi K. Hepsin, a putative cell-surface serine protease, is required for mammalian cell growth. Proc Natl Acad Sci U S A. 1993;90:7181-7185. 7.Srikantan V, Valladares M, Rhim JS, Moul JW, Srivastava S. HEPSIN inhibits cell growth/invasion in prostate cancer cells. Cancer Res. 2002;62:6812-6816. 8.Nakamura K, Nasu Y, Hongo A, et al. Hepsin shows inhibitory effects through apoptotic pathway on ovarian cancer cell lines. Int J Oncol. 2006;28:393-398. 9.Tanimoto H, Yan Y, Clarke J, et al. Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res. 1997;57:2884-2887. 10.Zacharski LR, Ornstein DL, Memoli VA, Rousseau SM, Kisiel W. Expression of the factor VII activating protease, hepsin, in situ in renal cell carcinoma. Thromb Haemost. 1998;79:876-877. 11.Magee JA, Araki T, Patil S, et al. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res. 2001;61:5692-5696. 12.Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature. 2001;412:822-826. 13.Welsh JB, Sapinoso LM, Su AI, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 2001;61:5974-5978. 14.Luo J, Duggan DJ, Chen Y, et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res. 2001;61:4683-4688. 15.Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell. 2004;6:185-195. 16.Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989;342:440-443. 17.Manfioletti G, Brancolini C, Avanzi G, Schneider C. The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol. 1993;13:4976-4985. 18.Schmidt C, Bladt F, Goedecke S, et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature. 1995;373:699-702. 19.Uehara Y, Minowa O, Mori C, et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature. 1995;373:702-705. 20.Kazama Y, Hamamoto T, Foster DC, Kisiel W. Hepsin, a putative membrane-associated serine protease, activates human factor VII and initiates a pathway of blood coagulation on the cell surface leading to thrombin formation. J Biol Chem. 1995;270:66-72. 21.Zacharski LR, Wojtukiewicz MZ, Costantini V, Ornstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost. 1992;18:104-116. 22.Wojtukiewicz MZ, Tang DG, Ciarelli JJ, et al. Thrombin increases the metastatic potential of tumor cells. Int J Cancer. 1993;54:793-806. 23.Yoshida E, Verrusio EN, Mihara H, Oh D, Kwaan HC. Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin. Cancer Res. 1994;54:3300-3304. 24.Nierodzik ML, Kajumo F, Karpatkin S. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Res. 1992;52:3267-3272. 25.Wu Q, Yu D, Post J, Halks-Miller M, Sadler JE, Morser J. Generation and characterization of mice deficient in hepsin, a hepatic transmembrane serine protease. J Clin Invest. 1998;101:321-326. 26.Yu IS, Chen HJ, Lee YS, et al. Mice deficient in hepsin, a serine protease, exhibit normal embryogenesis and unchanged hepatocyte regeneration ability. Thromb Haemost. 2000;84:865-870. 27.Herter S, Piper DE, Aaron W, et al. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J. 2005;390:125-136. 28.Kirchhofer D, Peek M, Lipari MT, Billeci K, Fan B, Moran P. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett. 2005;579:1945-1950. 29.Moran P, Li W, Fan B, Vij R, Eigenbrot C, Kirchhofer D. Pro-urokinase-type plasminogen activator is a substrate for hepsin. J Biol Chem. 2006. 30.Ried S, Jager C, Jeffers M, et al. Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor. J Biol Chem. 1999;274:16377-16386. 31.Hall CL, Tsan R, Mugnai G, Mazar A, Radinsky R, Pettaway CA. Enhanced invasion of hormone refractory prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA). Prostate. 2004;59:167-176. 32.Resnick D, Pearson A, Krieger M. The SRCR superfamily: a family reminiscent of the Ig superfamily. Trends Biochem Sci. 1994;19:5-8. 33.Sasaki T, Brakebusch C, Engel J, Timpl R. Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin. Embo J. 1998;17:1606-1613. 34.Grassadonia A, Tinari N, Iurisci I, et al. 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj J. 2004;19:551-556. 35.Xuan JA, Schneider D, Toy P, et al. Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture. Cancer Res. 2006;66:3611-3619. 36.Li Y, Yu DC, Chen Y, et al. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res. 2001;61:6428-6436. 37.Frankel S, Sohn R, Leinwand L. The use of sarkosyl in generating soluble protein after bacterial expression. Proc Natl Acad Sci U S A. 1991;88:1192-1196. 38. 岑運倩 利用鹼性磷酸酶與hepsin融合蛋白確認與hepsin相互作用之分子 國立台灣大學醫學院醫事技術學研究所碩士論文 2000 39. 蘇英卉 利用RAP in situ與Flag-hepsin重組融合蛋白研究與hepsin相作用之分子 國立台灣大學醫學院醫事技術學研究所碩士論文 2002 40. 王忠琳 Hepsin蛋白對人類癌細胞的影響 國立台灣大學醫學院醫事技術學研究所2004 41. John E. Coligan et al. Current Protocols In Protein Science, volume 1, 6.3.1 | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/31434 | - |
| dc.description.abstract | Hepsin屬第二型穿膜絲胺酸蛋白酶,普遍表現於各組織細胞,其中又以肝臟表現量最高。Hepsin能在缺乏組織因子下活化血液凝血第七因子,啟動外源性凝血反應;近幾年研究發現,hepsin在前列腺癌細胞株常是過量表現,而被推測與癌細胞的生長及轉移相關;。文獻指出hepsin可活化pro-HGF以及pro-uPA,然此功能仍缺乏活體內實驗證明。hepsin基因剔除小鼠不僅胚胎發育正常,成鼠也未出現凝血反應異常,所以目前對hepsin詳細生理功能及作用機轉仍不清楚。
為了研究hepsin的功能,本篇論文目標在製備抗hepsin抗體。首先,藉由大腸桿菌表現系統與Pichia pastoris酵母菌表現系統表現hepsin重組蛋白,成功使用大腸桿菌表現系統表現出人類hepsin基因重組蛋白以及小鼠hepsin基因重組蛋白,並將人類hepsin基因重組蛋白免疫小鼠。此外,為了分析將來作為抗體功能評估的方法,本論文也利用SK-Hep1的hepsin穩定表現細胞株建立活體動物實驗模式;於活體實驗中發現,表現突變型hepsin的肝癌細胞株其腫瘤生成能力較低。 | zh_TW |
| dc.description.abstract | Hepsin is a type II transmembrane serine protease, which is present in most tissues, with the highest expression level in liver. It is shown to interact with coagulation Factor VII, and convert zymogen factor VII to factor VIIa. Previous studies suggest that hepsin is involved in cell growth and migration. Hepsin was also shown to activate proHGF and pro-uPA by in vitro study. These findings are promising yet lacking of in vivo functional significance. Moreover, because embryonic developmental defects and hemorrhage abnormality were not shown in hepsin knockout mice. The biological role of hepsin remains unclear.
To study hepsin function, this study aims at generating anti-hepsin antibodies. E. coli and Pichia pastoris expression systems were used to produce the hepsin recombinant protein. In this study, I have expressed the human and mouse hepsin and used the human recombinant protein to generate the specific anti-human hepsin polyclonal antibody. Besides, to set up the in vivo tumorigenesis assay by inoculating the SK-Hep1 /hepsin stable clone into nude mice could be as a kind of functional assay of the generated antibodies. In the nude mice tumorigenesis assay, I discovered that the tumorigenesis ability of SK-Hep1 stable clone which express the mutant hepsin was lower than those express wild type hepsin or none. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T03:12:58Z (GMT). No. of bitstreams: 1 ntu-95-R93424019-1.pdf: 6082652 bytes, checksum: 40f943a89630d3d34e6ec21fcb64c232 (MD5) Previous issue date: 2006 | en |
| dc.description.tableofcontents | 目錄 2
縮寫表3 中文摘要4 英文摘要5 前言6 材料與方法12 結果21 討論25 未來研究方向29 圖30 表49 參考資料51 附錄55 | |
| dc.language.iso | zh-TW | |
| dc.subject | 絲胺酸蛋白酶 | zh_TW |
| dc.subject | 穿膜 | zh_TW |
| dc.subject | 腫瘤生成 | zh_TW |
| dc.subject | 蛋白表現 | zh_TW |
| dc.subject | 抗體製備 | zh_TW |
| dc.subject | tumorigenesis | en |
| dc.subject | serine protease | en |
| dc.subject | SRCR | en |
| dc.subject | hepsin | en |
| dc.title | 表現人類與小鼠Hepsin基因重組蛋白及抗體製備 | zh_TW |
| dc.title | Expression of human and mouse hepsin recombinant proteins and antibody generation | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 94-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 林淑容,高照村 | |
| dc.subject.keyword | 抗體製備,蛋白表現,穿膜,絲胺酸蛋白酶,腫瘤生成, | zh_TW |
| dc.subject.keyword | hepsin,SRCR,serine protease,tumorigenesis, | en |
| dc.relation.page | 67 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2006-08-31 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 醫學檢驗暨生物技術學研究所 | zh_TW |
| 顯示於系所單位: | 醫學檢驗暨生物技術學系 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-95-1.pdf 未授權公開取用 | 5.94 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
